Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
Joseph M. Flynn
No relevant relationships to disclose
John C. Byrd
Research Funding - Pharmacyclics
Thomas J. Kipps
Consultant or Advisory Role - Roche; Roche (U)
Research Funding - Roche
Michael Boxer
No relevant relationships to disclose
Kathryn S. Kolibaba
Research Funding - Gilead Sciences; Pharmacyclics; Roche
Nicola Tyson
Employment or Leadership Position - Roche
Stock Ownership - Roche
Jamie H. Hirata
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Jeff Porter Sharman
Research Funding - Genentech